Table 2.
Fixed vaccination posts catchment radius | Proportion of target population vaccinated within fixed post catchments* | Proportion of hard-to-reach target population vaccinated* | Proportion of total target population vaccinated* | Measles cases averted† | Deaths averted† | DALYs averted† | Direct medical costs averted† | Productivity losses averted† | Total societal costs averted† | Outreach vaccination strategy costs† |
---|---|---|---|---|---|---|---|---|---|---|
25% of Population that Received MCV! Receives MCV2 | ||||||||||
2.5 | MCV1: 100% | MCV1: 50% | MCV1: 74% | 43,858 | 7894 | 230,694 | 1,193,382 | 290,778,977 | 291,972,358 | 1,153,637 |
MCV2: 25% | MCV2: 13% | MCV2: 19% | (43,742–43,929) | (3,463–18,011) | (102,355–442,365) | (550,706–2,121,772) | (93,210,173–552,025,216) | (93,760,879–554,146,987) | (439,591–1,955,085) | |
5 | MCV1: 100% | MCV1: 50% | MCV1: 90% | 2877 | 518 | 15,133 | 78,285 | 19,074,967 | 19,153,252 | 521,940 |
MCV2: 25% | MCV2: 13% | MCV2: 22% | (2852–2863) | (228–1189) | (6673–28,834) | (35,901–138,301) | (6,076,371–33,994,263) | (6,112,272–34,132,564) | (187,397–891,469) | |
10 | MCV1: 100% | MCV1: 50% | MCV1: 97% | 55 | 10 | 290 | 1499 | 365,291 | 366,791 | 266,949 |
MCV2: 25% | MCV2: 13% | MCV2: 24% | (49–40) | (3–23) | (115–405) | (617–1941) | (504,891–504,891) | (506,831–506,831) | (79,432–497,655) | |
50% of Population that Received MCVI Receives MCV2 | ||||||||||
2.5 | MCV1: 100% | MCV1: 50% | MCV1: 74% | 42,246 | 7604 | 222,212 | 1,149,501 | 280,087,153 | 281,236,654 | 1,384,364 |
MCV2: 50% | MCV2: 25% | MCV2: 37% | (42,366–42,404) | (3380–17,431) | (99,136–427,009) | (533,383–2,048,117) | (90,278,170–532,862,383) | (90,811,553–534,910,500) | (527,509–2,346,102) | |
5 | MCV1: 100% | MCV1: 50% | MCV1: 90% | 938 | 169 | 4934 | 25,523 | 6,218,811 | 6,244,333 | 626,328 |
MCV2: 50% | MCV2: 25% | MCV2: 45% | (938–934) | (75–388) | (2196–9405) | (11,815–45,109) | (1,999,720–11,087,687) | (2,011,535–11,132,796) | (224,876–1,069,763) | |
10 | MCV1: 100% | MCV1: 50% | MCV1: 97% | 34 | 6 | 177 | 917 | 223,347 | 224,264 | 320,339 |
MCV2: 50% | MCV2: 25% | MCV2: 48% | (29–38) | (2–16) | (68–380) | (368–1821) | (473,834–473,834) | (475,656–475,656) | (95,319–597,187) | |
75% of Population that Received MCVI Receives MCV2 | ||||||||||
2.5 | MCV1: 100% | MCV1: 50% | MCV1: 74% | 41,620 | 7492 | 218,923 | 1,132,490 | 275,942,065 | 277,074,554 | 1,615,092 |
MCV2: 75% | MCV2: 38% | MCV2: 56% | (41,587–41,538) | (3323–17,064) | (97,313–418,286) | (523,578–2,006,276) | (88,618,544–521,976,488) | (89,142,122–523,982,763) | (615,427–2,737,119) | |
5 | MCV1: 100% | MCV1: 50% | MCV1: 90% | 313 | 56 | 1647 | 8519 | 2,075,659 | 2,084,178 | 730,716 |
MCV2: 75% | MCV2: 38% | MCV2: 67% | (319–313) | (25–131) | (746–3153) | (4013–15,121) | (679,144–3,716,806) | (683,157–3,731,927) | (262,356–1,328,667) | |
10 | MCV1: 100% | MCV1: 50% | MCV1: 97% | 33 | 6 | 171 | 886 | 215,862 | 216,748 | 373,729 |
MCV2: 75% | MCV2: 38% | MCV2: 72% | (37–36) | (2–15) | (87–367) | (468–1762) | (458,382–458,382) | (460,144–460,144) | (111,205–696,718) | |
100% of Population that Received MCVl Receives MCV2 | ||||||||||
2.5 | MCV1: 100% | MCV1: 50% | MCV1: 74% | 37,489 | 6748 | 197,192 | 1,020,077 | 248,551,653 | 249,571,730 | 1,845,819 |
MCV2: 100% | MCV2: 50% | MCV2: 74% | (37,513–37,466) | (2997–15,380) | (87,781–377,282) | (472,294–1,809,603) | (79,938,493–470,807,872) | (80,410,787–472,617,476) | (703,346–3,128,136) | |
5 | MCV1: 100% | MCV1: 50% | MCV1: 90% | 163 | 29 | 859 | 4446 | 1,083,204 | 1,087,650 | 835,104 |
MCV2: 100% | MCV2: 50% | MCV2: 90% | (163–160) | (13–67) | (382–1612) | (2057–7731) | (348,156–1,900,251) | (350,213–1,907,981) | (299,835–1,426,351) | |
10 | MCV1: 100% | MCV1: 50% | MCV1: 97% | 33 | 6 | 171 | 886 | 215,888 | 216,774 | 427,119 |
MCV2: 100% | MCV2: 50% | MCV2: 97% | (28–27) | (2–14) | (64–270) | (347–1293) | (336,361–336,361) | (337,654–337,654) | (127,092–796,249) |
MCV1 = first dose of measles-containing vaccine; MCV2 = second dose of measles-containing vaccine; MCV1 target population = eligible children < 12 months (i.e., surviving infants); MCV2 target population = eligible children 12–23 months;
Values are rounded to nearest whole number and cannot be used to reconstruct incremental cost-effectiveness ratios (ICERs) reported in the text, which used unrounded values. Note: Base value correspond to an outreach vaccination location catchment area radius of 10 km. Ranges represent the minimum and maximum values when varying parameters across their ranges, for an outreach vaccination location catchment area radius of 7.5–20 km. Logistics cost assumes a child is vaccinated every 15 min (2–30 min).